Amarin Corp Plc (AMRN)

[zumantu]

It’s possible AMRN valuation will be improved sooner by successfully treating the very disease most here dismissed as being hyped .

I suspect Vacsepa will be proven effective (dose dependent) in treating COVID19 by dampening cytokine storm, endothelial dysfunction, oxidative stress, NO production, reduced clotting - all factors in severe COVID19 outcomes.

Don’t expect PR - the initial results / outcomes will be via small clinical studies and shared via KOLS to direct to physicians, assoc.. The halo effect from COVID19 treatment will drive Rx as Vascepa therapeutic value recognized

Again, do not expect pumping PR
Should you have doubts watch MedCram on YouTube to learn how COVID19 is increasingly seen as a CVD issue and less a respiratory via ace2 receptor and cascade into oxidative stress, excessive clotting